In Depth 17 Feb 2025
Biotech’s legal storm: Why securities class action lawsuits are surging
Find out about what’s behind the increase of securities class action lawsuits in the biotech industry and how to prevent them.
In Depth
- Latest Posts
In Depth 12 Feb 2025
Dendritic cell therapy: Diakonos, Northwest Biotherapeutics and Mendus push ahead with next-generation candidates
Find out about the field of dendritic cell therapy, as several companies attempt to bring next-generation candidates through the clinic.
In Depth 10 Feb 2025
Monoclonal antibodies: are they the key to treating Alzheimer’s disease?
A major stride in treating Alzheimer’s disease has been the development of monoclonal antibodies.
In Depth 5 Feb 2025
Needle-free vaccines: Micron Biomedical, Vaxxas, and IntegriMedical bring their new technologies to patients
Discover the advantages of needle-free vaccines and which companies are developing their own promising delivery solutions in this space.
In Depth 4 Feb 2025
World Cancer Day: trends in cancer therapeutics to look forward to in 2025
As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer care in 2025.
In Depth 3 Feb 2025
The biggest biotech funding rounds in January 2025
The companies Immunovant, Verdiva Bio, and Akero Therapeutics bagged the biggest biotech funding rounds overall in January 2025.
ADVERTISEMENT
ADVERTISEMENT
In Depth 29 Jan 2025
Pancreatic cancer: Oncolytics Biotech, Candel, and CytomX bring promising therapies to the clinic
Discover the treatments currently being developed for pancreatic cancer, which has historically been extremely difficult to treat.
In Depth 24 Jan 2025
Why are there only 20 cell and gene therapies in Europe?
There are 20 cell and gene therapies on Europe’s market versus 43 in the U.S. Find out more about this ecosystem.
In Depth 23 Jan 2025
mRNA, RNAi, circRNA, ASOs: A comparative guide to RNA therapeutics
In this review of RNA therapies, we paint an overview of what’s going on in a field that could address a number of diseases.
In Depth 20 Jan 2025
Is biotech M&A set to surge in 2025?
There is big hope for biotech M&A in 2025, with a resounding sense that activity will rise again as several important factors come into play.
In Depth 17 Jan 2025
Are PD-1 and PD-L1 checkpoint inhibitors as good as we thought?
Checkpoint inhibitors, especially those targeting PD-1 and PD-L1, are exploding in popularity. But how much of it is hype?
In Depth 15 Jan 2025
CRISPR: The gene editing tool changing the world (2025 update)
CRISPR-Cas9 has changed the world with the promise of making gene editing much easier and faster than before. But what is its real potential?
ADVERTISEMENT
